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Abstract
Background: To investigate differences in perioperative outcomes by type of skin incision, transverse versus
vertical, for planned cesarean hysterectomy for placenta accreta spectrum (PAS).
Methods: A retrospective cohort study of all women who underwent a planned cesarean hysterectomy for
abnormal placentation at a single academic medical center over 5 years. The Student’s t-test was used for
continuous variables and Fisher’s exact test compared categorical variables. Continuous data were presented as
median and compared using the Wilcoxon-rank sum test.
Results: Forty-two planned cesarean hysterectomies were identified. A transverse skin incision was made in 43%
(n = 18); a vertical skin incision was made in 57% (n = 24). Skin incision was independent of BMI (30.3 vs 30.8 kg/m2,
p = 0.37), placental location (p = 0.82), and PAS-subtype (p = 0.26). Mean estimated blood loss (EBL) was 2.73 l (L)
(range 0.5–20) and was not significantly different between transverse and vertical skin incision (2.6 L vs 2.8 L, p =
0.8). There was significantly shorter operative time with transverse skin incision (180 vs 238 min, p = 0.03), with no
difference in intraoperative complications, including cystotomy (p = 0.22) and ureteral injury (p = 0.73).
Postoperatively, there was no difference in maternal length of stay (4.8 vs 4.4 days, p = 0.74) or post-operative
opioid use (117 vs 180 morphine equivalents, p = 0.31).
Conclusion: Transverse skin incision is associated with shorter operative time for patients undergoing planned
cesarean hysterectomy. There was no difference in EBL, intraoperative complications, postoperative length of stay,
or opioid use. Given an increasing rate of cesarean hysterectomy, we should consider variables that optimize
maternal outcomes and resource utilization.
Background
Placenta accreta spectrum (PAS), formerly known as
morbidly adherent placentation, is an increasingly com-
mon obstetrical complication associated with maternal
hemorrhage and subsequent morbidity and mortality
worldwide [1, 2]. While the rate of maternal mortality
continues to rise, hemorrhage remains a leading cause
[1–5]. PAS is classified on the invasiveness of tropho-
blastic tissue past the maternal decidua into the uterine
myometrium; namely, placenta accreta, increta, and per-
creta [1, 6, 7]. Both a history of previous cesarean
delivery (CD) and placenta previa are risk factors for
PAS [8]. Studies of the incidence of PAS in the United
States range from 1 in 272 pregnancies [9] to 1 in 731
pregnancies [10], and this risk increases with concurrent
placenta previa and increasing number of prior cesarean
deliveries [6, 9–12]. As the number of CDs increases in
the United States, the number of pregnancies affected by
PAS has increased [13].
The antepartum diagnosis of PAS is critical to opti-
mizing delivery planning given the significant maternal
and neonatal risks. Currently, the most widely accepted
delivery approach to PAS is planned cesarean hysterec-
tomy at 34 0/7 to 35 6/7 with the placenta left in situ
after delivery of the fetus [13–15]. Complications associ-
ated with PAS include life-threatening hemorrhage
necessitating urgent cesarean hysterectomy, damage to
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surrounding organs including the bowel, ureters, and
bladder at time of hysterectomy, severe coagulopathy,
transfusion-related complications, intensive care unit ad-
mission, and maternal death [2, 13]. Multidisciplinary
delivery planning teams are recommended to improve
maternal and neonatal morbidity [2, 13, 16].
There are currently no studies comparing maternal
and fetal outcomes related to type of skin, midline
vertical versus Pfannenstiel skin incision, for planned
cesarean hysterectomy with prenatally suspected PAS.
Rather, skin incision is left to surgeon preference [2, 13,
16]. The aim of this study is to compare perioperative
and postoperative outcomes of planned cesarean
hysterectomies performed by midline vertical versus
Pfanenstiel skin incision to better guide clinical practice
in optimizing maternal and neonatal outcomes in
pregnancies complicated by PAS.
Methods
A retrospective cohort study was performed utilizing all
birth records to include all births for planned cesarean
hysterectomy secondary to PAS at a single tertiary care
academic medical center over 5 years (January 1, 2014 -
July 30, 2018. Institutional review board (IRB) approval
was obtained from the University of California, Los
Angeles (IRB #18–000872). Planned cesarean hysterec-
tomy was defined as antepartum suspected placenta
accreta spectrum whereby a delivery plan had been
established involving a multidisciplinary team, including
obstetrics, perinatology, interventional radiology, ur-
ology, and anesthesia. Conservative management of PAS
was excluded. Patients with undiagnosed PAS at time of
delivery or patients who underwent emergent cesarean
hysterectomy due to heavy vaginal bleeding with concur-
rent maternal hemodynamic instability and/or category
II or III fetal heart tracing were excluded from analysis.
Antepartum diagnosis of PAS was made according to
established sonographic features by board-certified ma-
ternal fetal medicine physicians at a single academic
center. Sonographic features included loss of normal ret-
roplacental hypoechoic zone; multiple vascular lacunae
within the placenta; blood vessels or placental tissue
bridging uterine-placental margin, myometrial-bladder
interface, or crossing uterine serosa; retroplacental myo-
metrial thickness of < 1 mm; and/or numerous coherent
vessels visualized with 3-dimensional power Doppler in
basal view [8, 13].
Forty-two patients met inclusion criteria for planned
cesarean hysterectomy for placenta accreta spectrum.
Records were reviewed, and demographic and outcome
data were chart abstracted from antepartum notes, pre-
operative imaging results, operative reports, and postpar-
tum notes. Demographic data included maternal age,
race, ethnicity, body mass index (BMI), insurance type,
gravidity, and parity. Pertinent medical and surgical his-
tory data included number of prior cesarean deliveries
and prior uterine surgeries. Preoperative diagnosis of
PAS, presence of placenta previa, and placenta location
was obtained by review of preoperative imaging. Opera-
tive reports were reviewed for gestational age at delivery,
type of skin incision, type of anesthesia, estimated blood
loss (defined in liters (L)), blood products transfusion re-
quirements, surgery length (defined in minutes as time
from skin incision to skin closure), and intra-operative
complications. Post-operative records were reviewed for
length of intensive care unit (ICU) stay (measured in
days), length of hospital stay (measured in days), opioid
use (in terms of morphine equivalents), wound compli-
cations, and maternal death.
The Student’s t-test was used to analyze continuous
variables and Fisher’s exact test compared categorical
variables. Continuous data were presented as median
(interquartile range [IQR]) and compared using the
Wilcoxon-rank sum test. For all analyses, p-values were
two-way and the level of statistical significance was set
at p < 0.05.
Results
Forty-two planned cesarean hysterectomies for PAS
were identified. Demographic data are presented in
Table 1. The median maternal age at delivery was 33
years (IQR 30–36.8), and the median maternal body
mass index was 33.0 kg/m2 (IQR 26.0–35.5). The
majority of women were Caucasian (85.7%), 2.4% Black,
and 11.9% identified as other. Fifty percent of patients
were of Hispanic ethnicity, 40.5% were non-Hispanic
White, 2.4% identified as other, and 7.1% were unknown.
Forty-five percent (n = 19) of patients had an antenatal
diagnosis of placenta accreta based on imaging, while
19% (n = 8) had an antenatal diagnosis of placenta
increta, and 29% (n = 12) had an antenatal diagnosis of
placenta percreta. The remaining 3 patients (7%) had an
antenatal diagnosis of placenta previa or normal placen-
tation in the setting of a history of cesarean delivery.
The median gravidity and parity were four (IQR 3–6)
and 2.5 (IQR 1–4) with a history of two prior cesarean
sections (IQR 1–3). Eighty-three percent of all pregnan-
cies (n = 35) were complicated by placenta previa.
Median gestational age at delivery was 34.8 weeks (IQR
32.9–35.6).
A transverse skin incision was made in 43% (n = 18)
and a vertical skin incision in 57% (n = 24) of cases. This
was independent of placental location (p = 0.82), degree
of placental invasion (p = 0.26), BMI (p = 0.37), number
of prior cesarean sections (p = 0.65), and gestational age
at delivery (p = 0.26). (Table 2). The decision to perform
a transverse or vertical skin incision was based on pro-
vider preference. There were no preoperative criteria
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used to determine the type of skin incision used. All
transverse incisions were Pfannenstiel incisions.
Intraoperative data are presented in Table 3. There
were significantly more ureteral stents placed in the
vertical skin incision group than in the transverse skin
incision group (p = 0.003), however there was no differ-
ence in placement of endovascular balloon catheters
(p = 0.33). There was no significant difference in mean
estimated blood loss (EBL) between the transverse (2.6
L) versus vertical (2.8 L) skin incision groups (p = 0.82).
Transfusion requirements were not different between
groups with average number of total units transfused at
5.06 in the transverse skin incision group versus 4.19 in
the vertical skin incision group (p = 0.71).
The type of skin incision modulated a significant dif-
ference in mean operative time between the two groups
with transverse skin incision requiring 180min on aver-
age compared to vertical skin incision at 238 (p = 0.03).
There was no difference in operative complications. The
overall incidence of intraoperative unintended organ in-
jury was 23.8% (n = 10). There were five cases of cystot-
omy in the transverse skin incision cohort versus three
cases in the vertical skin incision cohort (relative risk
(RR) 1.55; 95% CI 0.52–4.62, p = 0.42). There was one
case of ureteral injury in the transverse skin incision co-
hort versus two cases in the vertical skin incision cohort
(RR 0.67; 95% CI 0.06–6.69, p = 0.73). The relative risk
of overall intraoperative organ injury was not statistically
Table 2 Type of skin incision by preoperative patient
characteristics
Preoperative factor Transverse incision
N = 18 (43%)
Vertical incision
N = 24 (57%)
P-value
BMI (kg/m2) 30.3 30.8 0.37
Placental location 0.82
Previa 15 22
Anterior or fundal 2 2
Posterior 1 0
Type of PAS (antenatal diagnosis) 0.26
Accreta 7 12
Increta 6 10
Percreta 2 9
Previa only 1 0
No PAS 2 0
Median # prior CD 2.1 2.3 0.65
Median GA at delivery
(weeks)
34.7 33.9 0.26
Transverse versus vertical skin incision as function of body mass index (BMI,
measured in kilograms (kg) per meters (m) squared), placental location, type
of placenta accreta spectrum (PAS) made by antenatal diagnosis
preoperatively, median number of prior cesarean deliveries (CD), and median
gestational age (GA) at delivery in weeks
Table 1 Demographic data
Demographics
Demographic Median (IQR)
Maternal age (years) 30 (30–36.8)
BMI (kg/m2) 33.0 (26.0–35.5)
GA (weeks) 34.8 (32.9–35.6)
Gravidity 4 (3–6)
Parity 2.5 (1–4)
Prior cesarean 2 (1–3)
Race/ethnicity N (%)
Hispanic 21 (50%)
Non-Hispanic white 17 (40.5%)
Black 1 (2.4%)
Other/unknown 3 (7.1%)
Type of PAS (antenatal diagnosis) N (%)
Previa only 1 (2%)
Accreta 19 (46%)
Increta 8 (19%)
Percreta 12 (29%)
Normal 2 (4%)
Demographic data presented include maternal age (in years), body mass index
(BMI), gestational age (GA), gravidity, parity, and number or prior cesarean
deliveries of all patients included in this study. Median is shown with
associated interquartile range (IQR). Race/ethnicity presented as a percentage
of the total number of subjects in the study. Type of placenta accreta
spectrum (PAS) made by antenatal diagnosis preoperatively is shown as a
percentage of the total number of subjects in the study
Table 3 Intraoperative outcomes
Intraoperative outcome Transverse incision
N = 18 (43%)
Vertical incision
N = 24 (57%)
P-value
Use of ureteral stent 2 14 0.003
Use of aortic balloon 15 22 0.33
Mean EBL (L) (SD) 2.6 (1.9) 2.8 (3.8) 0.82
Transfusion requirements
Mean # pRBCs (SD) 3.28 (4.47) 2.79 (5.00) 0.75
Mean # platelets (SD) 0.28 (0.57) 0.25 (0.61) 0.88
Mean # FFP (SD) 1.33 (2.35) 1.00 (1.93) 0.62
Mean #
cryoprecipitate (SD)
0.17 (0.38) 0.13 (0.35) 0.75
Mean total #
products (SD)
5.06 (7.63) 4.19 (7.67) 0.71
Mean operative time
(minutes) (SD)
180 (86) 238 (74) 0.03
Intraoperative complications 0.42
Cystotomy 5 3 0.22
Ureteral Injury 1 2 0.72
Intraoperative surgical outcome data presented include use of ureteral stents,
aortic balloon, estimated blood loss (EBL) in liters (L) (with standard deviation
(SD)), transfusion requirements with packed red blood cells (pRBCs), platelets,
fresh frozen plasma (FFP), cryoprecipitate, and total number of products,
operative time, and intraoperative complications including cystotomy and
ureteral injury
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significant between the two groups (RR 1.55; 95% CI
0.52–4.62, p = 0.42).
Postoperative data are presented in Table 4. Postoper-
atively, there was no significant difference in the length
of hospital stay between the transverse vs vertical skin
incision groups (p = 0.64). There was no significant
difference in average intensive care unit length of stay
(p = 0.64) or postoperative opioid use (p = 0.22). From
the time of delivery to the 6-week postpartum follow-up
visit, there were no wound complications with the trans-
verse skin incision cohort; in comparison, 2 cases of
wound complications occurred in the vertical skin
incision cohort, both of which were superficial wound
separation (p = 0.16). There were no maternal or fetal
deaths in either group.
Discussion
We demonstrate no significant differences in objective
measures of surgical morbidity, including EBL, blood
transfusions, and unintended organ damage for planned
cesarean hysterectomy for PAS as a function of skin
incision, transverse versus vertical. Vertical skin incision
was associated with longer operative time; however,
there was no difference in length of hospital stay or
post-operative morphine equivalents used. To our
knowledge, there is no data evaluating the type of skin
incision performed for planned cesarean hysterectomies.
Transverse incision appears a reasonable option in
appropriately selected patients when compared to a ver-
tical skin incision.
Decreasing any possible risks associated with morbid-
ity related to PAS must be assessed both independently
and as part of multidisciplinary surgical checklists. With
the increasing incidence of PAS, measures to optimize
maternal and fetal outcomes at the time of surgery are
critical.
Prior studies have addressed other ways to decrease
maternal and neonatal morbidity, including the use of
multidisciplinary teams in planning scheduled cesarean
hysterectomies, preoperative placement of ureteral stents
to minimize ureteral injury, and preoperative endovascu-
lar interventions such as balloon catheter or arterial
embolization [16–21]. Two studies have independently
concluded that when compared with standard obstetric
care, the use of multidisciplinary teams consisting of
maternal fetal medicine specialists, anesthesia, neonatol-
ogists, interventional radiologists, urologists, and nursing
in preparing for scheduled cesarean hysterectomies
significantly reduces rates of large-volume blood transfu-
sions, reoperation rates within 7 days for complications,
intensive care unit admissions, and prolonged postopera-
tive hospital stays [16, 17]. A meta-analysis found similar
results, however did not show any difference in postop-
erative hospital length of stay [18].
Studies evaluating the use of preoperative ureteral
stents to reduce of risk of urologic injury at time of
cesarean hysterectomy have yielded conflicting results
[2, 19, 20]. A recent review of the evidence in 2019 by
Collins et al. found that use of ureteral stents may be
useful in reducing the risk of ureteral injury in cases of
placenta percreta; however, the current evidence is not
strong enough to recommend their routine use [2].
Crocetto et al. showed that ureteral stents in association
with cesarean hysterectomy do not reduce the risk of
urinary tract injury in cases of placenta accrete [19]. A
systematic review in 2012 by Tam Tam et al. found that
the use of ureteral stents significantly reduces the risk of
urologic injury in cesarean hysterectomies [20].
Using endovascular interventions such as balloon
catheters or arterial embolization for cesarean hysterec-
tomies remains a controversial topic, as it is difficult to
predict for which patients the benefits of these interven-
tions outweigh the risks, and whether their use reduces
transfusion requirements [2, 21]. A meta-analysis by
D’Antonio et al. in 2019 found that while the use of
endovascular interventions significantly reduced the risk
of blood loss greater than 2.5 L, there was no difference
in transfusion requirements [21]. This study found a
complication rate of approximately 5%, however reliable
data on complication rates for use of endovascular inter-
ventions at time of cesarean hysterectomy are lacking [21].
The recent review by Collins et al. concluded that large,
prospective, controlled studies on the use of endovascular
interventions are necessary to recommend their routine use
at time of scheduled cesarean hysterectomy [2].
We demonstrate that the only statistically significant
difference in surgical outcome was seen with mean op-
erative time in that transverse skin incision was nearly
60 min less than for vertical skin incision. This finding
may be explained by the higher frequency of ureteral
stent placement in the vertical skin incision group,
which may indirectly reflect a higher degree of difficulty
of cesarean hysterectomies in the vertical skin incision
group. Another contributing factor may be secondary to
Table 4 Postoperative outcomes
Postoperative outcome Transverse incision
N = 18 (43%)
Vertical incision
N = 24 (57%)
P-value
Mean postop
LOS (days) (SD)
4.8 (3.1) 4.4 (1.5) 0.64
Mean ICU LOS
(days) (SD)
0.45 (0.69) 0.62 (1.07) 0.64
Mean postop opioid
use (ME) (SD)
117 (96) 180 (131) 0.22
Wound complications 0 2 0.16
Postoperative surgical outcomes data presented included mean postoperative
length of stay (LOS) in days, mean intensive care unit (ICU) LOS in days, mean
postoperative opioid use measured by morphine equivalents (ME), and wound
complications. There were no fetal or maternal deaths
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increased provider comfort with opening and closing
transverse incisions than vertical incisions because the
tissue is generally on less tension than vertical incisions,
and the underlying bowel is better protected by the ab-
dominal wall musculature during fascial closure with a
Pfannenstiel incision than with a midline vertical inci-
sion. This outcome is important for numerous reasons.
The first is that with the increasing incidence of preg-
nancies affected by PAS, resource utilization becomes
integral. While the vertical skin incision group had more
ureteral stents placed, there were no differences in ur-
eteral injury between both groups. Shorter operative
time signifies less cost to the patient and the hospital,
more operating room availability for other uses, and
greater availability of surgeons, anesthesiologists, and
other personnel. Second, shorter operating times may
yield greater patient safety and satisfaction due to less
time under anesthesia and therefore fewer anesthesia-
related risks [22].
Others have described higher opioid use in patients
who underwent vertical skin incision and conclude that
a vertical abdominal incision is more painful than trans-
verse abdominal incisions [23]. Our sample size may not
have allowed assessment of all outcome variables, such
as a difference in postoperative wound separation which
has been described with vertical skin incisions because
of the notion that incisions on greater tension are at
greater risk of wound separation [23, 24].
There are no studies that have addressed perioperative
outcomes based on the type of skin incision at the time
of scheduled cesarean hysterectomy, transverse versus
vertical. The review by Collins et al. acknowledges that
there is no evidence to guide recommendations for type
of skin incision, and consensus opinion concludes that
type of skin incision should be left to the operating team
[2]. Our study is the first that is designed to specifically
answer this question.
One of the strengths of this study is that the type of
skin incision performed was independent of patient
BMI, placental location, type of abnormal placentation,
gestational age, and number of prior cesarean sections.
Therefore, the number of potentially important con-
founders is limited, as some of these variables alone have
been shown to affect intraoperative outcomes, including
blood loss, injury to surrounding organs, and length of
surgery [25–28].
We recognize that our study has limitations. First, its
retrospective nature captures a heterogenous disease
(PAS). Nearly half of the patients in this study had
placenta accreta, which is associated with less severe
surgical morbidity in comparison to deeper degrees of
invasion as is seen with placenta increta or placenta per-
creta. Secondly, our analysis was specific to a single
health care system at a large, academic, tertiary care
hospital that serves a diverse population; however, this
could potentially limit the applicability of our findings.
Third, varying surgical skill among surgeons and degree
of difficulty of each cesarean hysterectomy may account
for differences in length of time of surgery. For those
cases in which the surgeon perceived the preoperative
degree of difficulty to be high may have been more likely
to perform a vertical skin incision. This limitation may
be supported by the fact that significantly more ureteral
stents were placed in the vertical skin incision group.
Fourth, the small sample size may not have enough
statistical power to identify significant differences in out-
come metrics or morbidity. We were unable to fully
control for all relevant confounding variables. Lastly, we
had limited ability to evaluate differences in outcome
metrics or safety given our small sample size and unable
to account for patient-driven and provider-driven deci-
sions related to skin incision.
Conclusion
Placenta accreta spectrum is a condition with increasing
incidence and maternal morbidity. Pre-, intra- and post-
operative techniques to attenuate risk are essential. Our
study suggests that transverse skin incision in our cohort
is associated with similar surgical outcomes and similar
rates of maternal morbidity, while decreasing operative
time. Larger studies are needed to elucidate surgical
methods and measures to optimize standard of care for
this high-risk patient cohort. This study postulates that
the difference in operative time could be clinically
relevant, and powering a future study to investigate this
outcome will be our next step.
Abbreviations
BMI: Body mass index; CD: Cesarean delivery; EBL: Estimated blood loss;
FFP: Fresh frozen plasma; GA: Gestational age; ICU: Intensive care unit;
IQR: Interquartile range; IRB: Institutional review board; Kg: Kilogram; L: Liters;
LOS: Length of stay; M: Meters; ME: Morphine equivalents; PAS: placenta
accreta spectrum; pRBC: Packed red blood cells; RR: Relative risk;
SD: Standard deviation
Acknowledgements
None.
Authors’ contributions
AS participated in project development, data collection, data analysis, and
manuscript writing. JM participated in data analysis, and manuscript writing.
YA participated in project development, data analysis, and manuscript
writing. KT participated in project development, and manuscript writing. All
authors read and approved the final version of this manuscript.
Funding
We are grateful to the National Center for Advancing Translational UCLA
CTSI Grant UL1TR001881 for funding (to Yalda Afshar) This funding source
was not involved in the study design, data collection, results analysis,
interpretation of data, or writing of the manuscript.
Availability of data and materials
The datasets during and/or analyzed during the current study available from
the corresponding author on reasonable request.
Szlachta-McGinn et al. BMC Pregnancy and Childbirth           (2020) 20:65 Page 5 of 6
Ethics approval and consent to participate
This article does not contain any studies with human participants or animals
performed by any of the authors. This study received approval from the
UCLA research ethics committee, the Institutional Review Board (IRB) at the
University of California, Los Angeles to access patient data. The study is IRB
approved (IRB #18–000872). Patient data was de-identified upon data
collection.
Informed consent: Informed consent not required for this retrospective
study.
Consent for publication
Not applicable.
Competing interests
Alec Szlachta-McGinn declares that he has no conflict of interest. Jenny de-
clares that she has no conflict of interest. Khalil Tabsh declares that he has
not conflict of interest. Yalda Afshar declares that she has no conflict of
interest.
Author details
1Department of Obstetrics and Gynecology, University of California, Los
Angeles, CA, USA. 2Division of Maternal Fetal Medicine, Department of
Obstetrics and Gynecology, University of California, 10833 Le Conte Avenue,
Room 27-139 CHS, Los Angeles, CA 90095-1740, USA.
Received: 18 November 2019 Accepted: 24 January 2020
References
1. Silver R, Branch W. Placenta Accreta Spectrum. N Engl J Med. 2018;378(16):
1529–36.
2. Collins SL, Alemdar B, van Beekhuizen HJ, et al. International Society for
Abnormally Invasive Placenta (IS-AIP). Evidence-based guidelines for the
management of abnormally invasive placenta: recommendations from the
International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol.
2019;220(6):511.
3. Kilpatrick S, Berg C, Bernstein P, et al. Standardized severe maternal
morbidity review: rationale and process. Obstet Gynecol.
2014;124(2 Pt 1):361–6.
4. Main E, McCain C, Morton C, et al. Pregnancy-related mortality in California:
causes, characteristics, and improvement opportunities. Obstet Gynecol.
2015;125(4):938–47.
5. Ozimek J, Eddins R, Greene N, et al. Opportunities for improvement in care
among women with severe maternal morbidity. Am J Obstet Gynecol. 2016;
215(4):509 e501–6.
6. Usta IM, Hobeika EM, Musa AA, et al. Placenta previa-accreta: risk factors and
complications. Am J Obstet Gynecol. 2005;193:1045–9.
7. Shellhaas CS, Gilbert S, Landon MB, et al. The frequency and complication
rates of hysterectomy accompanying cesarean delivery. Eunice Kennedy
Shriver National Institutes of Health and human development maternal-fetal
medicine units network. Obstet Gynecol. 2009;114:224–9.
8. Jauniaux E, Collins S, Burton G. Placenta accreta spectrum: pathophysiology
and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet
Gynecol. 2018;218(1):75–87.
9. Eshkoli T, Weintraub AY, Sergienko R, et al. Placenta accreta: risk factors,
perinatal outcomes, and consequences for subsequent births. Am J Obstet
Gynecol. 2013;208:219.e1–7.
10. Bailit JL, Grobman WA, Rice MM, et al. Morbidly adherent placenta
treatments and outcomes. Obset Gynecol. 2015;125(3):683–9.
11. Bowman ZS, Eller AG, Bardsley TR, et al. Risk factors for placenta accreta: a
large prospective cohort. Am J Perinatol. 2014;31:799–804.
12. Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with
multiple repeat cesarean deliveries. National Institute of Child Health and
Human Development maternal-fetal medicine units network. Obstet
Gynecol. 2006;107:1226–32.
13. Cahill A, Beigi R, Heine P, et al. Placenta Accreta Spectrum. Obstetric care
consensus no. 7. American College of Obstetricians and Gynecologists.
Obstet Gynecol. 2018;132:e259–75.
14. Gyamfi-Bannerman C. Society for Maternal-Fetal Medicine (SMFM) consult
series #44: management of bleeding in the late preterm period. Society for
Maternal-Fetal Medicine (SMFM). Am J Obstet Gynecol. 2018;218:B2–8.
15. Gyamfi-Bannerman C, Gantt A, Miller R, et al. Medically indicated late-
preterm and early-term deliveries. ACOG Committee opinion no. 764.
American College of Obstetricians and Gynecologists. Obstet Gynecol.
2019;133:e151–5.
16. Eller AG, Bennett MA, Sharshiner M, et al. Maternal morbidity in cases of
placenta accreta managed by a multidisciplinary care team compared with
standard obstetric care. Obstet Gynecol. 2011;117(2 Pt 1):331.
17. Shamshirsaz AA, Fox KA, Salmanian B, et al. Maternal morbidity in patients
with morbidly adherent placenta treated with and without a standardized
multidisciplinary approach. Am J Obstet Gynecol. 2015;212(2):218.e1–9.
18. Bartels HC, Rogers AC, O'Brien D, et al. Association of Implementing a
multidisciplinary team approach in the Management of Morbidly
Adherent Placenta with Maternal Morbidity and Mortality. Obstet
Gynecol. 2018;132(5):1167.
19. Crocetto F, Esposito R, Saccone R, et al. Use of routine ureteral stents in
cesarean hysterectomy for placenta accreta. J Matern Fetal Neonatal Med.
2019. https://doi.org/10.1080/14767058.2019.1609935.
20. Tam Tam KB, Dozier J, Nello Martin JR. Approaches to reduce urinary tract
injury during management of placenta accreta, increta, and percreta: a
systematic review. J Matern Fetal Neonatal Med. 2012;25(4):329–34.
21. D'Antonio F, Iacovelli A, Liberati M, et al. Role of interventional radiology in
pregnancy complicated by placenta accreta spectrum disorder: systematic
review and meta-analysis. Ultrasound Obstet Gynecol. 2019;53(6):743.
22. Phan K, Kim JS, Kim JH, et al. Anesthesia duration as an independent
risk factor for early postoperative complications in adults undergoing
elective ACDF. Global Spine J. 2017;7(8):727–34. https://doi.org/10.1177/
2192568217701105.
23. Brown SR, Tiernan J. Transverse verses midline incisions for abdominal
surgery. Cochrane Database of Systematic Reviews; 2005, Issue 4. Art. No.:
CD005199. https://doi.org/10.1002/14651858.CD005199.pub2.
24. Burger J, van’t Reit M, Jeekel J. Abdominal incisions: techniques and
postoperative complications. Scand J Surg. 2002;91:315–21.
25. Shields L, Goffman D, Caughey A. ACOG Practice Bulletin No. 183.
Postpartum Hemorrhage. Vol 4, No. 130; 2017.
26. Blomberg M. Maternal obesity and risk of postpartum hemorrhage. Obstet
Gynecol. 2011 Sep;118(3):561–8.
27. Butwick A, et al. Risk factors for severe postpartum hemorrhage after
cesarean delivery: case-control studies. Anesth Analg. 2017;125(2):523–32.
28. Tarnay CM. Bladder Injury During Cesarean Delivery. Curr Womens Health
Rev. 2013;9(2):70–6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Szlachta-McGinn et al. BMC Pregnancy and Childbirth           (2020) 20:65 Page 6 of 6
